Biologics and Biosimilars
-10%
portes grátis
Biologics and Biosimilars
Drug Discovery and Clinical Applications
Xie, Hong-Guang; Feng, Xiaodong; Malhotra, Ashim; Yang, Catherine F.
Taylor & Francis Ltd
06/2022
510
Dura
Inglês
9781138594227
15 a 20 dias
1133
Descrição não disponível.
Chapter 1: Biologics and Biosimilars 101: Principles and Practice. Chapter 2: Frontiers in Biopharmaceutical Development of Biologics and Biosimilars: Opportunities and Challenges Chapter 3: Biologics and Biosimilars: Research and Development. Chapter 4: Vaccines as Biologics in the Era of Pandemic. Chapter 5: Therapeutic Delivery Systems for Biologics and Biosimilars. Chapter 6: Legislative and Regulatory Pathways for Biosimilars. Chapter 7: The Development of Biologics from the Perspective of the Pharmaceutical Industry. Chapter 8: The Manufacturing and Quality Assurance Process for Biologics and Biosimilars. Chapter 9: Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Biological Products. Chapter 10: Understanding Variability, Stability, and Immunogenicity of Biosimilars. Chapter 11: Expanding the Product Shelf: Taking Biologics and Biosimilars from the Bench to the Bedside. Chapter 12: Hydrogel-Based Delivery of Biologics in Cancer and Cardiovascular Diseases: Proof-of-Concept. Chapter 13: Clinical Use of Biologics and Biosimilars in Oncology Settings. Chapter 14: Monoclonal Antibodies in Cancer Therapeutics. Chapter 15: Molecule-Targeted Drugs That Treat Colorectal Cancer. Chapter 16: Rising from the Ashes: The Curious Case of the Development of Biologics for the Treatment of Neuroblastoma. Chapter 17: Paradigm Shift in Cancer Therapy: Chimeric Antigen Receptor T Cell Therapy. Chapter 18: Biologics and Biosimilars Used for Diabetes. Chapter 19: Clinical Use of Biologics and Biosimilars in Asthma. Chapter 20: Biologics and Biosimilars: Potential Therapeutics for Autoimmune Renal Diseases. Chapter 21: Therapeutics of Recombinant Human Clotting Factor VIII (rhFVIII) for Hemophilia A. Chapter 22: Complement as New Immunotherapy Target: Past, Present, and Future. Chapter 23: Drug Discovery Approaches for Inflammatory Bowel Disease: Antibodies and Biosimilars. Chapter 24: Transformative Stem Cell-Based Therapy in Neurological Diseases and Beyond. Chapter 25: Biologics and Biosimilars: Clinical Applications and Biomarker Testing. Chapter 26: Application of Modeling and Simulation in the Development of Biologics and Biosimilars. Chapter 27 Machine Learning Applications in Biologics and Biosimilars: Disruptive Innovation.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Drug development;Targeted therapy and precision medicine associated with biologic and biosimilars;Cost analysis and pharmacoeconomics;Biosimilar drugs differ from generic drugs;Novel biotechnology;Health care policy decision making;Biosimilar Product;Reference Product;TMDD Model;Biosimilar Market;mRNA Vaccine;Biological Products;Chimeric Antigen Receptor T-cell Therapy;DNA Vaccine;Autoimmune Renal Diseases;ICIs;TMDD;Indication Extrapolation;Biosimilar Medicines;FDA Approval;BLA;Atypical Hemolytic Uremic Syndrome;PD L1 Expression;C1 Esterase Inhibitor;PHSA;C3 Convertase;Triple Negative Breast Cancer;Th1 Cells;Endogenous IgG;Spike Protein;Interchangeable Products
Chapter 1: Biologics and Biosimilars 101: Principles and Practice. Chapter 2: Frontiers in Biopharmaceutical Development of Biologics and Biosimilars: Opportunities and Challenges Chapter 3: Biologics and Biosimilars: Research and Development. Chapter 4: Vaccines as Biologics in the Era of Pandemic. Chapter 5: Therapeutic Delivery Systems for Biologics and Biosimilars. Chapter 6: Legislative and Regulatory Pathways for Biosimilars. Chapter 7: The Development of Biologics from the Perspective of the Pharmaceutical Industry. Chapter 8: The Manufacturing and Quality Assurance Process for Biologics and Biosimilars. Chapter 9: Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Biological Products. Chapter 10: Understanding Variability, Stability, and Immunogenicity of Biosimilars. Chapter 11: Expanding the Product Shelf: Taking Biologics and Biosimilars from the Bench to the Bedside. Chapter 12: Hydrogel-Based Delivery of Biologics in Cancer and Cardiovascular Diseases: Proof-of-Concept. Chapter 13: Clinical Use of Biologics and Biosimilars in Oncology Settings. Chapter 14: Monoclonal Antibodies in Cancer Therapeutics. Chapter 15: Molecule-Targeted Drugs That Treat Colorectal Cancer. Chapter 16: Rising from the Ashes: The Curious Case of the Development of Biologics for the Treatment of Neuroblastoma. Chapter 17: Paradigm Shift in Cancer Therapy: Chimeric Antigen Receptor T Cell Therapy. Chapter 18: Biologics and Biosimilars Used for Diabetes. Chapter 19: Clinical Use of Biologics and Biosimilars in Asthma. Chapter 20: Biologics and Biosimilars: Potential Therapeutics for Autoimmune Renal Diseases. Chapter 21: Therapeutics of Recombinant Human Clotting Factor VIII (rhFVIII) for Hemophilia A. Chapter 22: Complement as New Immunotherapy Target: Past, Present, and Future. Chapter 23: Drug Discovery Approaches for Inflammatory Bowel Disease: Antibodies and Biosimilars. Chapter 24: Transformative Stem Cell-Based Therapy in Neurological Diseases and Beyond. Chapter 25: Biologics and Biosimilars: Clinical Applications and Biomarker Testing. Chapter 26: Application of Modeling and Simulation in the Development of Biologics and Biosimilars. Chapter 27 Machine Learning Applications in Biologics and Biosimilars: Disruptive Innovation.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Drug development;Targeted therapy and precision medicine associated with biologic and biosimilars;Cost analysis and pharmacoeconomics;Biosimilar drugs differ from generic drugs;Novel biotechnology;Health care policy decision making;Biosimilar Product;Reference Product;TMDD Model;Biosimilar Market;mRNA Vaccine;Biological Products;Chimeric Antigen Receptor T-cell Therapy;DNA Vaccine;Autoimmune Renal Diseases;ICIs;TMDD;Indication Extrapolation;Biosimilar Medicines;FDA Approval;BLA;Atypical Hemolytic Uremic Syndrome;PD L1 Expression;C1 Esterase Inhibitor;PHSA;C3 Convertase;Triple Negative Breast Cancer;Th1 Cells;Endogenous IgG;Spike Protein;Interchangeable Products
